|

Ulixertinib Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: BVD-523

Pipeline

Early 1: 1Phase 1: 2Phase 2: 1

Top Sponsors

  • M.D. Anderson Cancer Center2
  • UNC Lineberger Comprehensive Cancer Center1
  • Memorial Sloan Kettering Cancer Center1

Indications

  • Cancer4
  • Histiocytic Neoplasms1
  • Gliomas1
  • Tumor, Solid1
  • Pancreatic Cancer1

Houston, Texas2 trials

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

M D Anderson Cancer Center

Phase 1
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

M D Anderson Cancer Center

Early 1

Rochester, Minnesota1 trial

Ulixertinib in People With Histiocytic Neoplasms

Mayo Clinic (Data Collection Only)

Phase 2

Chapel Hill, North Carolina1 trial

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Lineberger Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.